Intervention

2-deoxy-2-[18F]fluoro-D-glucose (FDG)

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting0

Common conditions5

Lead sponsors shown2

Clinical trials

2 shown

PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer PatientNCT03295695 · 2020-12-01

WITHDRAWN

A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With ErlotinibNCT00453362 · 2006-12-01

COMPLETED

Common conditions

Breast Cancer1 Breast Cancer, Female1 Breast Cancer, Male1 Breast Neoplasms1 Non-Small Cell Lung Cancer1

Leading sponsors

Genentech, Inc.1 H. Lee Moffitt Cancer Center and Research Institute1

Trial status mix

COMPLETED1

WITHDRAWN1

Phase mix

EARLY_PHASE11

PHASE11

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.